The Korean Radiation Oncology Group (KROG) assessed the value of Deauville score (DS) on <sup>18</sup>F-fluorodeoxyglucose Positron emission tomography-computed tomography (FDG PET/CT) as a predictor of recurrence and survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy in diffuse large B-cell lymphoma (DLBCL).
In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), <sup>18</sup> F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementary modality that could replace CT, especially in young patients.
High total metabolic tumor volume (TMTV) calculated using <sup>18</sup> F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL.
The study objective was to compare the prognostic value of interim and end-of-treatment FDG PET/CT using five therapeutic evaluation criteria in patients with diffuse large B cell lymphoma (DLBCL).
We aimed to assess the predictive value of visually-assessed interim <sup>18</sup>F-FDG PET on progression-free survival (PFS) or event-free survival (EFS) in DLBCL patients treated with first-line immuno-chemotherapy regimens.
The present study was to evaluate the functional parameters of <sup>18</sup>F-FDG PET/CT in patients with testicular diffuse large B-cell lymphoma (DLBCL).
The present study aims to evaluate the prognostic meaning of bone marrow FDG uptake pattern in PET/CT of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients.
We evaluated the usefulness of interim <sup>18</sup>F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
The aim of the present study was to determine the role of changes in metabolic tumor volume (MTV) between baseline and interim <sup>18</sup>F-FDG PET/CT scans, following three courses of chemotherapy in order to predict complete response (CR) and overall survival (OS) in patients with DLBCL.
A high F-FDG uptake was found in mammary lesions in a 36-year-old woman who underwent a PET/CT scan for initial staging of diffuse large B-cell lymphoma.
Interobserver Agreement of Interim and End-of-Treatment <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials.
As in HL, the predictive value of FDG-PET after induction therapy of diffuse large B-cell lymphoma is higher than that of CT alone so that we obtain relevant prognostic information unavailable through anatomical imaging.
TVSR measured on the initial <sup>18</sup>F-FDG PET is an independent prognostic factor in DLBCL and has an additional prognostic value when combined with TMTV, IPI score and chemotherapy.
The ROC curve demonstrated that the percentage of maximum difference-value of SUVmax (or T/N ratio) on F-FDG PET images could effectively differentiate multicentric gliomas from multiple DLBCLs, with a cut-off value of 44.4%, sensitivity of 64.7%, and specificity of 100% (P < .001).Percentage of maximum difference-value of SUVmax (or T/N ratio) on F-FDG PET images might be a potential indicator for distinguishing multicentric gliomas from intracranial multiple DLBCLs, which might help determine the treatment strategy.